American Ginseng (Cereboost™)

COMMON NAME

American Ginseng

TOP BENEFITS OF CEREBOOST™

Enhances working memory and alertness*

Promotes calmness*

Supports cognitive function and performance*

WHAT IS CEREBOOST™?

Panax quinquefolius is commonly called American ginseng, because it is native to forested regions in North America. It is the same genus as Asian ginseng (Panax ginseng) and prized for many of the same reasons. Both American and Asian ginseng contain similar active constituents called ginsenosides. The ginsenosides are thought to be responsible for many of the adaptogenic (i.e., stress and fatigue support)  and health-promoting properties associated with ginseng^.[1] While there are many different ginsenosides, the most well characterized include Rb1, Rb2, Rg1, Rc, Rd, and Re. Cereboost™ is a clinically studied and standardized American ginseng root extract. In humans studies, Cereboost™ has enhanced working memory and alertness, while promoting calmness.*

Qualia CEREBOOST™ SOURCING

Cereboost™ has been used in human clinical studies, where it has enhanced alertness, working memory, and calmness.

Cereboost™ was granted the NutrAward 2010 for the Best New Ingredient of the year.

Cereboost™ is produced by Naturex, an innovator in nutraceutical products in Europe and the United States.

Cereboost™ is standardized for total ginsenoside content (10-12%), and several specific ginsenosides, including Rb1 (4-7%), Rb2 (0.2-1.5%), Rg1 (0.1-0.4%), Rc (0.5-3.5%), Rd (0.9-3.0%), and Re (0.4-3.5%). 

Cereboost™ is non-GMO, gluten-free, and vegan.

Cereboost™ is a trademark of Naturex.

CEREBOOST™ DOSING PRINCIPLES AND RATIONALE

We consider Panax quinquefolius to be in the adaptogenic herb category; following hormetic dosing principles (see Neurohacker Dosing Principles) with a high likelihood of having a hormetic range (i.e., a dosing range below and above which results could be poorer). We have selected to dose this at an amount that is consistent with the studied amount in the human clinical studies for supporting working memory, alertness, and calmness.*

PANAX QUINQUEFOLIUS KEY MECHANISMS

Supports brain function and cognition*

Supports attention [2]

Supports working memory [2,3]

Supports learning and memory [4–7]

Modulates cholinergic neurotransmission [1,4,5,8,9]

Influences acetylcholinesterase (AChE) activity [4]

Supports choline acetyltransferase (ChAT) expression [4]

Supports acetylcholine levels [4]

Influences dopaminergic neurotransmission [10–13]

Influences GABAergic neurotransmission [1,14]

Supports neuroprotective functions [1,4,5,8,14,15]

Supports healthy neural cytokine signaling [1,8,14,16]

Supports neurite outgrowth, dendritic spine density, and synaptic plasticity [1,5–7]

Supports BDNF signaling [1,7,8,17]

Supports neurogenesis [1,8,17]

Supports a healthy mood*

Promotes calmness [2]

Supports mood [1,14,18]

Supports adaptogenic actions (i.e., stress resilience and anti-fatigue) [5]

Supports healthy stress signaling and HPA-axis activation [1,14] 

Supports antioxidant defenses*

Supports brain antioxidant defenses [14]

Replenishes glutathione (GSH) levels [14]

Counters lipid peroxidation [14]

Supports healthy cardiometabolic function*

Supports healthy cardiometabolic parameters [19–21]

Supports healthy blood glucose levels [22–24]

Supports healthy insulin sensitivity [25]

Supports fat metabolism [19]

Supports mitochondrial enzyme complex activities [14]

Supports a healthy gut microbiota*

Supports healthy gut immune signaling [26–28]

Supports a healthy gut microbiota composition [27,28]

Promotes exercise performance* 

Supports high-intensity endurance performance [29,30]

Supports healthy muscle responses to exercise [29–31]

*These statements have not been evaluated by the Food and Drug Administration.  This product is not intended to diagnose, cure, or prevent any disease.

REFERENCES 

[1]H.J. Kim, P. Kim, C.Y. Shin, J. Ginseng Res. 37 (2013) 8–29.

[2]A. Scholey, A. Ossoukhova, L. Owen, A. Ibarra, A. Pipingas, K. He, M. Roller, C. Stough, Psychopharmacology 212 (2010) 345–356.

[3]A. Ossoukhova, L. Owen, K. Savage, M. Meyer, A. Ibarra, M. Roller, A. Pipingas, K. Wesnes, A. Scholey, Hum. Psychopharmacol. 30 (2015) 108–122.

[4]K. Shin, H. Guo, Y. Cha, Y.-H. Ban, D.W. Seo, Y. Choi, T.-S. Kim, S.-P. Lee, J.-C. Kim, E.-K. Choi, J.-M. Yon, Y.-B. Kim, Regul. Toxicol. Pharmacol. 78 (2016) 53–58.

[5]Y. Cheng, L.-H. Shen, J.-T. Zhang, Acta Pharmacol. Sin. 26 (2005) 143–149.

[6]I. Mook-Jung, H.S. Hong, J.H. Boo, K.H. Lee, S.H. Yun, M.Y. Cheong, I. Joo, K. Huh, M.W. Jung, J. Neurosci. Res. 63 (2001) 509–515.

[7]H. Zhao, Q. Li, X. Pei, Z. Zhang, R. Yang, J. Wang, Y. Li, Behav. Brain Res. 201 (2009) 311–317.

[8]K. Radad, R. Moldzio, W.-D. Rausch, CNS Neurosci. Ther. 17 (2011) 761–768.

[9]C.G. Benishin, Neurochem. Int. 21 (1992) 1–5.

[10]G.-L. Wang, Y.-P. Wang, J.-Y. Zheng, L.-X. Zhang, Brain Res. 1699 (2018) 44–53.

[11]S.H. Lee, J. Hur, E.H. Lee, S.Y. Kim, Biomol. Ther. 20 (2012) 482–486.

[12]H.S. Kim, Y.T. Hong, K.W. Oh, Y.H. Seong, H.M. Rheu, D.H. Cho, S. Oh, W.K. Park, C.G. Jang, Gen. Pharmacol. 30 (1998) 783–789.

[13]H.S. Kim, K.S. Kim, K.W. Oh, Pharmacol. Biochem. Behav. 63 (1999) 407–412.

[14]P. Chanana, A. Kumar, Front. Neurosci. 10 (2016) 84.

[15]Y.C. Kim, S.R. Kim, G.J. Markelonis, T.H. Oh, J. Neurosci. Res. 53 (1998) 426–432.

[16]C.F. Wu, X.L. Bi, J.Y. Yang, J.Y. Zhan, Y.X. Dong, J.H. Wang, J.M. Wang, R. Zhang, X. Li, Int. Immunopharmacol. 7 (2007) 313–320.

[17]L.-H. Shen, J.-T. Zhang, Neurol. Res. 26 (2004) 422–428.

[18]M. Chatterjee, P. Verma, G. Palit, Indian J. Exp. Biol. 48 (2010) 306–313.

[19]R.K. Singh, E. Lui, D. Wright, A. Taylor, M. Bakovic, Can. J. Physiol. Pharmacol. 95 (2017) 1046–1057.

[20]V. Vuksan, Z.Z. Xu, E. Jovanovski, A.L. Jenkins, U. Beljan-Zdravkovic, J.L. Sievenpiper, P. Mark Stavro, A. Zurbau, L. Duvnjak, M.Z.C. Li, Eur. J. Nutr. (2018).

[21]I. Mucalo, E. Jovanovski, D. Rahelić, V. Božikov, Z. Romić, V. Vuksan, J. Ethnopharmacol. 150 (2013) 148–153.

[22]V. Vuksan, M.P. Stavro, J.L. Sievenpiper, V.Y. Koo, E. Wong, U. Beljan-Zdravkovic, T. Francis, A.L. Jenkins, L.A. Leiter, R.G. Josse, Z. Xu, J. Am. Coll. Nutr. 19 (2000) 738–744.

[23]V. Vuksan, J.L. Sievenpiper, V.Y. Koo, T. Francis, U. Beljan-Zdravkovic, Z. Xu, E. Vidgen, Arch. Intern. Med. 160 (2000) 1009–1013.

[24]V. Vuksan, J.L. Sievenpiper, J. Wong, Z. Xu, U. Beljan-Zdravkovic, J.T. Arnason, V. Assinewe, M.P. Stavro, A.L. Jenkins, L.A. Leiter, T. Francis, Am. J. Clin. Nutr. 73 (2001) 753–758.

[25]L.R. De Souza, A.L. Jenkins, E. Jovanovski, D. Rahelić, V. Vuksan, J. Ethnopharmacol. 159 (2015) 55–61.

[26]C.-Z. Wang, H. Yao, C.-F. Zhang, L. Chen, J.-Y. Wan, W.-H. Huang, J. Zeng, Q.-H. Zhang, Z. Liu, J. Yuan, Y. Bi, C. Sava-Segal, W. Du, M. Xu, C.-S. Yuan, Int. Immunopharmacol. 64 (2018) 246–251.

[27]C.-Z. Wang, C. Yu, X.-D. Wen, L. Chen, C.-F. Zhang, T. Calway, Y. Qiu, Y. Wang, Z. Zhang, S. Anderson, Y. Wang, W. Jia, C.-S. Yuan, Cancer Prev. Res. 9 (2016) 803–811.

[28]C.-Z. Wang, W.-H. Huang, C.-F. Zhang, J.-Y. Wan, Y. Wang, C. Yu, S. Williams, T.-C. He, W. Du, M.W. Musch, E.B. Chang, C.-S. Yuan, Clin. Transl. Oncol. 20 (2018) 302–312.

[29]J. Wu, S. Saovieng, I.-S. Cheng, T. Liu, S. Hong, C.-Y. Lin, I.-C. Su, C.-Y. Huang, C.-H. Kuo, J. Ginseng Res. (2018).

[30]C.-W. Hou, S.-D. Lee, C.-L. Kao, I.-S. Cheng, Y.-N. Lin, S.-J. Chuang, C.-Y. Chen, J.L. Ivy, C.-Y. Huang, C.-H. Kuo, PLoS One 10 (2015) e0116387.

[31]M. Estaki, E.G. Noble, Appl. Physiol. Nutr. Metab. 40 (2015) 116–121.